Defining the extent of cables loss in endometrial cancer subtypes and its effectiveness as an inhibitor of cell proliferation in malignant endometrial cells in vitro and in vivo

Cancer Biology and Therapy

Volumn 4, Issue 1, 2005, Pages 110-114

  DeBernardo, Robert L ^a   Littell, Ramey D ^a   Luo, Hongwei ^a   Duska, Linda R ^a   Oliva, Esther ^a   Kirley, Sandra D ^a   Lynch, Maureen P ^a   Zukerberg, Lawrence R ^a   Rueda, Bo R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Endometrial cancer; Steroid regulation; Tumor suppressor

Indexed keywords

ANTIGESTAGEN; ANTIMITOTIC AGENT; BINDING PROTEIN; CABLES PROTEIN; ESTROGEN; MESSENGER RNA; MIFEPRISTONE; PROGESTERONE; UNCLASSIFIED DRUG; CABLES1 PROTEIN, HUMAN; CARRIER PROTEIN; CYCLINE; PHOSPHOPROTEIN; PROGESTERONE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BENIGN TUMOR; CANCER GRADING; CELL DIFFERENTIATION; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CYSTADENOCARCINOMA; DOSE RESPONSE; DRUG EFFICACY; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ESTROGEN BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; MITOSIS INHIBITION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; ADENOCARCINOMA; ANIMAL; CELL CULTURE; CELL PROLIFERATION; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; ENDOMETRIUM TUMOR; GENE EXPRESSION PROFILING; GENETICS; PATHOLOGY; PHYSIOLOGY;

ADENOCARCINOMA; ADENOCARCINOMA, CLEAR CELL; ANIMALS; CARRIER PROTEINS; CELL PROLIFERATION; CYCLINS; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MICE; PHOSPHOPROTEINS; RECEPTORS, PROGESTERONE; TUMOR CELLS, CULTURED;

EID: 24644435508     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.1.1433     Document Type: Article

References (19)

1. Emons G, Fleckenstein G, Hinney B, Huschmand A, Heyl W. Hormonal interactions in endometrial cancer. Endocr Relat Cancer 2000; 7:227-42.
2. Kaaks R, Lukanova A, Kurzer MS. Obesity endogenous hormones and endometrial cancer risk: A synthetic review. Cancer Epidemiol Biomarkers Prev 2002; 11:1531-43.
3. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: From a phenotypical to a molecular-based classification. Virchows Arch 2004; 444:213-23.
4. American Cancer Society: What are the key statistics for endometrial cancer? 2004 (Facts and Figures 2004).
5. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15:10-7.
6. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000; 92:924-30.
7. Matias-Guiu X, Catasus L, Bussaglia E, Lagarda H, Garcia A, Pons C, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001; 32:569-77.
8. Salvesen HB, Akslen LA. Molecular pathogenesis and prognostic factors in endometrial carcinoma. Apmis 2002; 110:673-89.
9. Zukerberg LR, DeBernardo RL, Kirley SD, D'Apuzzo M, Lynch MP, Littell RD, et al. Loss of cables, a cyclin-dependent kinase regulatory protein, is associated with the development of endometrial hyperplasia and endometrial cancer. Cancer Res 2004; 64:202-8.
10. Wu CL, Kirley SD, Xiao H, Chuang Y, Chung DC, Zukerberg LR. Cables enhances cdk2 tyrosine 15 phosphorylation by Weel, inhibits cell growth, and is lost in many human colon and squamous cancers. Cancer Res 2001; 61:7325-32.
11. Zukerberg LR, Patrick GN, Nikolic M, Humbert S, Wu CL, Lanier LM, et al. Cables links Cdk5 and c-Abl and facilitates Cdk5 tyrosine phosphorylation, kinase upregulation, and neurite outgrowth. Neuron 2000; 26:633-46.
12. Matsuoka M, Matsuura Y, Semba K, Nishimoto I. Molecular cloning of a cyclin-like protein associated with cyclin-dependent kinase 3 (cdk 3) in vivo. Biochem Biophys Res Commun 2000; 273:442-7.
13. Rubin SC, Federici MG, Lloyd KO, Lewis Jr JL, Hoskins WJ. Characterization of a human endometrial carcinoma cell line producing intraperitoneal tumor growth in immunodeficient mice. Gynecol Oncol 1992; 45:273-8.
14. Rueda BR, Botros IW, Pierce KI, Regan JW, Hoyer PB. Comparison of the mRNA levels for the PGF2CC receptor (FP) during luteolysis and early pregnancy in the ovine corpus luteum. Endocrine 1995; 3:781-7.
15. Lahav-Baratz S, Ben-Izhak O, Sabo E, Ben-Eliezer S, Lavie O, Ishai D, et al. Decreased level of the cell cycle regulator p27 and increased level of its ubiquitin ligase Skp2 in endometrial carcinoma but not in normal secretory or in hyperstimulated endometrium. Mol Hum Reprod 2004; 10:567-72.
16. Semczuk A, Boltze C, Marzec B, Szczygielska A, Roessner A, Schneider-Stock R. p16INK4A alterations are accompanied by aberrant protein immunostaining in endometrial carcinomas. J Cancer Res Clin Oncol 2003; 129:589-96.
17. Roh JW, Kim JW, Park NH, Song YS, Park IA, Park SY, et al. p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. Gynecol Oncol 2004; 93:499-505.
18. Kip1 in estrogen-related Endometrial adenocarcinomas. Clin Cancer Res 2003; 9:5332-8.
19. Dong Q, Kirley S, Rueda B, Zhao C, Zukerberg L, Oliva E. Loss of cables, a novel gene on chromosome 18q, in ovarian cancer. Mod Pathol 2003; 16:863-8.